Other Healthcare B2B
61 confirmed failures
Funding Burned
$642.6M
Median Lifespan
12 years
Dominant Failure
Preclinical Capital Exhaustion
25% of cases
Period
1998 — 2023
Failure Pattern Distribution
Ran out of money before clinical trials15 (25%)
Couldn't prove the product worked14 (23%)
Preclinical science did not translate8 (13%)
Outspent by bigger competitors7 (11%)
Regulation moved faster than the company4 (7%)
Sold through the wrong channel3 (5%)
Couldn't get paid by insurance3 (5%)
Multi-stakeholder approval bottleneck3 (5%)
Customer acquisition costs too high2 (3%)
Product claims exceeded actual capabilities1 (2%)
Couldn't connect to existing systems1 (2%)
Curator's Note
auto-generatedThis section of the registry contains 61 healthcare Other Healthcare B2B startups that shut down between 1998 and 2023, representing $642.6M in combined funding. The dominant failure pattern is Preclinical Capital Exhaustion (25% of cases). Clinical Validation Gap accounts for another 23%. These entries were coded using the Gioia three-level qualitative methodology. Inter-rater reliability: 0.82 (strong agreement). This note is auto-generated and will be replaced by editorial analysis.
Have a correction? Reach out.
Cost of Inaction
Cost of Inaction — Workflow Cost
Cost of Inaction — Startup Risk
Building in other healthcare b2b? Stress-test your thesis against these 61 failures.